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Poster Session-II 129during therapy in patients with cGVHD, and correlating cell num-
bers with response.
Methods:We studied 25 adult pts with histories of hematological
malignancies who developed cGVHD after allogeneic, HLA-
matched HPCT. At the time of ECP initiation, pts were either de-
pendent upon corticosteroids for control of cGvHD (21 pts), or ste-
roid-intolerant (4 pts). A good response was defined as having. 50%
reduction in the corticosteroid dose within 4 months of starting
ECP, with improved or stable lesions on skin and other sites. For ste-
roid-intolerant pts, improvement in skin condition was used to iden-
tify responders. PBMCs were analyzed before ECP began and every
2 months during ECP therapy. The numbers of plasmacytoid DCs
(pDC, Lin-CD1231CD11c-HLA-DR1), myeloid DCs (mDC,
Lin-CD123-CD11c1HLA-DR1), and CD41 and CD81 T-cells
in blood were determined by flow cytometry.
Results:Themedian number of ECP treatments was 26 (range 2–
68). Fourteen pts (56%) had good response, and 11 were non-re-
sponders. Responders had an estimated 2-yr survival of 88% after
starting ECP, vs 18% for non-responders (p 5 0.004). Responders
had higher baseline numbers of pDCs (average 5.8 vs. 0.6 cells/
mcL, p 5 0.025) and mDCs (average 15 vs. 3.8 cells/mcL, p 5
0.01) compared with non-responders. Baseline CD41 T-cell num-
bers were higher in responders compared with non-responders (av-
erage 623 vs. 178 cells/mcL, p 5 0.005), as were CD81 T-cell
numbers (712 vs. 251 cells/mcL, p 5 0.047). There was no correla-
tion between incidence of infection and numbers of T-cells or DCs,
or response to ECP. Contrary to the original hypothesis, there were
no consistent changes in the numbers of circulating DCs and T-cells
among responders over a 12-month period.
Conclusion:Our results demonstrate that higher numbers of cir-
culating DCs and T-cells predict response to ECP in pts with
cGVHD. Response to ECP was significantly associated with im-
proved survival in univariate and multivariate analyses (p\0.03).
Our findings support a newer model for the mechanism of response
to ECP therapy, involving interactions between donor-derived DCs
and donor T-cells.359
POST-TRANSPLANT IMMUNOTHERAPY FOR PEDIATRIC ALL
Qin, H., Capitini, C.M., Wayne, A.S., Fry, T.J. National Institutes of
Health, Bethesda, MD
Background: Pediatric Acute Lymphoblastic Leukemia (ALL) is
the most common childhood malignancy. Despite substantial ad-
vancements in upfront therapy, management of patients with relapse
remains one of the difficult challenges in pediatric oncology. Alloge-
neic transplantation can be curative for relapsing ALL, in part due to
a graft versus leukemia effect. The ability to develop these ap-
proaches has been limited by lack of suitable pre-clinical models of
pediatric ALL. Thus, we sought to develop a murine model of pedi-
atric ALL to explore post-transplant immunotherapeutic strategies.
Methods: E2A-PBX1 is a translocation that occurs in approxi-
mately 5% of pediatric ALL. We utilized leukemia cells from
E2A-PBX1 transgenic/CD3epsilon -/- mice that spontaneously de-
velop precursor B cell ALL (Bijl J. et al. Gene & Development
19:224–233, 2005) to establish a transplantable ALL model.
Results: After conditioning in stem cell media, E2a-PBX1 cells
could be cultured in vitro and generated leukemia consistently.
The phenotype and pattern of dissemination is analogous to pediat-
ric pre-B ALL. Immunization with dendritic cells (DC) pulsed with
irradiated E2A-PBX1 cells protected against the development of leu-
kemia.We next sought to establish a bonemarrow transplant (BMT)
model of minimal residual disease (MRD). Injection of E2A-PBX1
cells prior to lethal irradiation and injection of minor MHC antigen
mismatched BMT resulted in the development of leukemia in two to
four weeks post BMT thus mimicking a model of minimal residual
disease. Ongoing experiments are exploring the ability to treat
MRD with DC vaccination, adoptive T cell transfer, drugs or com-
bination therapy.
Conclusions:We have established a transplantable model of pre-
B cell ALL that mimics pediatric ALL, can be prevented by vaccines,
and develop following anMRD state in allogeneic BMT.This model
provides an excellent system to test strategies to diminish relapse fol-
lowing allogeneic transplantation for pediatric ALL.360
DAY7 TNFR1 LEVELS FOLLOWING REDUCED INTENSITY ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT (HCT) PREDICT FOR ACUTE
GVHD
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Tumor necrosis factor-a (TNF) is significant in the pathogenesis
of GVHD. We have previously shown that early rises in soluble
TNF receptor 1 (TNFR1) levels measured on day 7 following mye-
loablative (MA) allogeneic HCT predict the development of GVHD
and TRM. In the setting of reduced intensity conditioning (RIC)
GVHD rates are similar to MA even though GVHD onset is often
delayed. We therefore hypothesized that TNFR1 levels on day 7
would correlate with GVHD after RIC. TNFR1 levels were mea-
sured on day 7 post-HCT in 156 pts (median age 56.6y, range 7–
71y) who underwent RIC HCT between 2000 to 2008. Pre-HCT
conditioning was Fludarabine (125–180 mg/m2) and Busulfan (6.4–
8.0 mg/kg) 6 total lymphoid irradiation (2–4 Gy) in 142 pts, with
minor variations in 14 pts, including 6 that received ATG. GVHD
prophylaxis was tacrolimus (day -3 to 180) and short-course metho-
trexate (5 mg/m2 on day 1,3,6,11 in 99 pts) or mycophenolate (day 0–
28 in 57 pts). There were 47 related donor (RD) pts (30%), 109 un-
related donor (URD) pts (70%) and 34 pts received single antigen
mismatched HCT (6 RD, 28 URD). The incidence of GVHD 2–4
was 49% in URD and 39% in RD. The median day of GVHD onset
was 32d (range 6–162d); 56d in the RD and 30d in the URD (p 5
0.02). The logarithm of TNFR1 levels was used for the analysis in
order to normalize right-skewed values. Regression analysis revealed
that a doubling in day 7 TNFR1 levels increased the risk of GVHD
2–4 by 1.36 times (p5 0.007), however, the risk appeared to be pri-
marily in the URD pts [Table 1]. Consistent with this observation,
the median day 7 TNFR1 level was significantly higher in pts devel-
oping GVHD 2–4 after URD (11.4 vs 11.0, p 5 0.01), but not after
RD RIC HCT (11.3 vs 11.1, p 5 0.38). Using the median TNFR1
level in URD HCT as a threshold, we found that pts with day 7
TNFR1 levels above the median were more likely to develop
GVHD 2–4 (p 5 0.008). This correlation remained significant
(p 5 0.01) after adjustment for pt age, gender and HLA match.
We conclude that for pts undergoing RIC HCT, a higher day 7
TNFR1 level correlates with incidence of GVHD 2–4. This effect
of TNFR1 on GVHD was strongest in the URD setting where do-
nor response to host alloantigens is more robust and GVHD de-
velops more quickly. The informative value of a day 7 TNFR1
level decreases in RD pts who develop GVHD a median of 7 weeks
later, suggesting that GVHD in the RD RIC setting is not strongly
dependent on conditioning induced TNF release.
Association of TNFR1 with Risk of GVHD 2-4
Donor Risk Ratio* p-valueOverall (n5156) 1.36 0.007
RD (n547) 1.22 0.44
URD (n5109) 1.42 0.006*Risk Ratio is for a doubling of TNFR1 levels361
DENILEUKIN DIFITOX (ONTAK) FOR THE TREATMENT OF ADVANCED
STEROID-REFRACTORY GVHD: SINGLE INSTITUTION EXPERIENCE
Abar, F.1, Leis, J.F.2, Jacoby, C.E.1, Mishra, M.1, Bubalo, J.S.1,
Curtin, P.T.3, Hayes-Lattin, B.L.1, Meyers, G.1, Slater, S.E.1,
Subbiah, N.1, Maziarz, R.T.1 1OHSU; 2Mayo; 3UCSD
Steroid Resistant (SR)-GVHD is associated with high mortality
when in encountered in allogeneic stem cell transplantation . Deni-
leukin Diftitox (DD), a recombinant fusion protein composed of the
cytocidal A chain of Diphtheria toxin and binding portion of IL-2,
has potent activity against activated CD251 T cells important in
the etiology of GVHD. It has been reported that DDmay have ther-
apeutic activity for the treatment of SR-GHVD (Ho et al, BLOOD
2004). This approach was adopted within our institution for
